BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/1/2022 9:20:54 AM | Browse: 392 | Download: 1062
 |
Received |
|
2022-03-05 04:32 |
|
Peer-Review Started |
|
2022-03-05 04:34 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-27 17:08 |
|
Revised |
|
2022-03-30 17:35 |
|
Second Decision |
|
2022-07-01 03:09 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-07-06 03:36 |
|
Articles in Press |
|
2022-07-06 03:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-06-28 02:17 |
|
Typeset the Manuscript |
|
2022-07-22 02:56 |
|
Publish the Manuscript Online |
|
2022-08-01 09:20 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Abu Taiub Mohammed Mohiuddin Chowdhury, Aktar Kamal, Md Kafil Uddin Abbas, Md Rezaul Karim, Md Ahsan Ali, Shubhashis Talukder, H M Hamidullah Mehedi, Hamid Hassan, Abul Hossain Shahin, Ya-Rui Li and Shui-Xiang He |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shui-Xiang He, PhD, Professor, Department of Gastroenterology, The First affiliated hospital of Xi’an Jiaotong University, Yanta Road, Xi'an 710061, Shaanxi Province, China. dyyyjxk@mail.xjtu.edu.cn |
| Key Words |
COVID-19; SARS-Cov-2; Famotidine; COVID-19 acute respiratory distress syndrome; COVID-19 treatment; Bangladesh |
| Core Tip |
Treatment with famotidine demonstrated a comparatively better outcome in the survival rates of patients. A rapid recovery time, less duration of intensive care unit (ICU) stay among the survivors, favorable improvement in the computed tomography findings and an earlier viral clearance were observed in the famotidine treatment group which differ significantly in a t-test (P ≤ 0.05). The difference between the time to symptomatic recovery, ICU stay duration and the national early warning score-2 on discharge was not significant however, mean values were relatively less than the control. Nevertheless, survival benefit was not significant with the famotidine as an added treatment for severe coronavirus disease 2019. |
| Publish Date |
2022-08-01 09:20 |
| Citation |
Mohiuddin Chowdhury ATM, Kamal A, Abbas MKU, Karim MR, Ali A, Talukder S, Hamidullah Mehedi HM, Hassan H, Shahin AH, Li YR, He SX. Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial. World J Clin Cases 2022; 10(23): 8170-8185 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i23/8170.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i23.8170 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
